Site icon

Legal protection against Unfair Competition In India

Legal protection against Unfair Competition In India

Legal protection against Unfair Competition In India

Legal protection against Unfair Competition In India

 

A act or practice in the course of industrial or commercial activities contrary to honest practices constitutes an act of unfair competition; which is against “contrary to honest practices”.

 

Behaviour classified as unfair competition:

To prevent unfair practice certain actions are limited by law.  Unfair business practices into three broad categories:

Acts causing confusion:

 

Acts those are misleading:

 

Acts damaging goodwill or reputation:

 

Protection against unfair competition:

  1. The Minister may by legislative instrument make Regulations for the effective implementation.
  2. A person who is damaged or considers that he is likely to be damaged by an act of unfair competition may bring an action for:

 

 

Cases:

Re Lakhanpal National Ltd. v. MRTP Commission

It was held that the representation that NOVINO batteries are manufactured in joint venture or in collaboration with National Panasonic is false and misleading where appellant company was manufactured NOVINO (dry cell) batteries in collaboration with M/s. Mitsushita Electric Industrial Company of Japan, and not with National Panasonic of Japan using their techniques, as advertised by it.

Re Bombay Tyres International Limited

In this the respondent company was supplying tyres to TELCO under the brand name ‘modistones’ which, however, were not manufactured by it, but by Modi Rubber Limited at Modipuram. But the commission holding that no UTP was involved closed the enquiry.

 

Re Glaxo Ltd and Capsulation Services Ltd

In the course of the inquiry it was found:

  1. The said drug was manufactured and packed by Capsulation on the basis of technical know-how supplied
  2. As per its quality control standard
  3. product was not an inferior product.
  4. The price of this drug compared well with similar products manufactured by other leading pharmaceutical manufacturers.

The commission held that the ingredient of loss or injury being absent, even though the impugned practice may fall under one or more clauses of Section 36 A of the MTRP Act, it is not an unfair trade practice.

 

 

Exit mobile version